159 related articles for article (PubMed ID: 7655739)
1. The prevalence and clinical significance of chromogranin A and secretogranin II immunoreactivity in colorectal adenocarcinomas.
Ferrero S; Buffa R; Pruneri G; Siccardi AG; Pelagi M; Lee AK; Coggi G; Bosari S
Virchows Arch; 1995; 426(6):587-92. PubMed ID: 7655739
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical distribution of chromogranins A and B and secretogranin II in neuroendocrine tumours of the gastrointestinal tract.
Fahrenkamp AG; Wibbeke C; Winde G; Ofner D; Böcker W; Fischer-Colbrie R; Schmid KW
Virchows Arch; 1995; 426(4):361-7. PubMed ID: 7599788
[TBL] [Abstract][Full Text] [Related]
3. Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: neuroendocrine expression in patients untreated and treated with androgen deprivation therapy.
Pruneri G; Galli S; Rossi RS; Roncalli M; Coggi G; Ferrari A; Simonato A; Siccardi AG; Carboni N; Buffa R
Prostate; 1998 Feb; 34(2):113-20. PubMed ID: 9465942
[TBL] [Abstract][Full Text] [Related]
4. Chromogranin gene expressions in colorectal adenocarcinomas.
Pagani A; Papotti M; Abbona GC; Bussolati G
Mod Pathol; 1995 Aug; 8(6):626-32. PubMed ID: 8532695
[TBL] [Abstract][Full Text] [Related]
5. Endocrine cells and prognosis in patients with colorectal carcinoma.
Hamada Y; Oishi A; Shoji T; Takada H; Yamamura M; Hioki K; Yamamoto M
Cancer; 1992 Jun; 69(11):2641-6. PubMed ID: 1571893
[TBL] [Abstract][Full Text] [Related]
6. Endocrine cells in colorectal adenocarcinomas: incidence, hormone profile and prognostic relevance.
de Bruïne AP; Wiggers T; Beek C; Volovics A; von Meyenfeldt M; Arends JW; Bosman FT
Int J Cancer; 1993 Jul; 54(5):765-71. PubMed ID: 8100808
[TBL] [Abstract][Full Text] [Related]
7. Chromogranins A and B and secretogranin II in hormonally identified endocrine cells of the gut and the pancreas.
Buffa R; Marè P; Gini A; Salvadore M
Basic Appl Histochem; 1988; 32(4):471-84. PubMed ID: 3223865
[TBL] [Abstract][Full Text] [Related]
8. Detection of chromogranin A in human gastric adenocarcinomas using a sensitive immunohistochemical technique.
Qvigstad G; Sandvik AK; Brenna E; Aase S; Waldum HL
Histochem J; 2000 Sep; 32(9):551-6. PubMed ID: 11127976
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine differentiation in colorectal carcinomas: assessing its prognostic significance.
Atasoy P; Ensari A; Demirci S; Kurşun N
Tumori; 2003; 89(1):49-53. PubMed ID: 12729362
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical comparison of chromogranins A and B and secretogranin II with calcitonin and calcitonin gene-related peptide expression in normal, hyperplastic and neoplastic C-cells of the human thyroid.
Schmid KW; Kirchmair R; Ladurner D; Fischer-Colbrie R; Böcker W
Histopathology; 1992 Sep; 21(3):225-32. PubMed ID: 1356907
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and prognostic significance of endocrine cells in colorectal adenocarcinomas.
Lapertosa G; Baracchini P; Delucchi F
Pathologica; 1994 Apr; 86(2):170-3. PubMed ID: 7936761
[TBL] [Abstract][Full Text] [Related]
12. Chromogranin A and B and secretogranin II in medullary carcinomas of the thyroid.
Schmid KW; Fischer-Colbrie R; Hagn C; Jasani B; Williams ED; Winkler H
Am J Surg Pathol; 1987 Jul; 11(7):551-6. PubMed ID: 3300386
[TBL] [Abstract][Full Text] [Related]
13. Immunological studies on the occurrence and properties of chromogranin A and B and secretogranin II in endocrine tumors.
Weiler R; Fischer-Colbrie R; Schmid KW; Feichtinger H; Bussolati G; Grimelius L; Krisch K; Kerl H; O'Connor D; Winkler H
Am J Surg Pathol; 1988 Nov; 12(11):877-84. PubMed ID: 2847571
[TBL] [Abstract][Full Text] [Related]
14. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours.
Stridsberg M; Oberg K; Li Q; Engström U; Lundqvist G
J Endocrinol; 1995 Jan; 144(1):49-59. PubMed ID: 7891024
[TBL] [Abstract][Full Text] [Related]
15. Secretoneurin in bronchopulmonary carcinoids--immunohistochemical comparison with chromogranins A and B and secretogranin II.
Tötsch M; Padberg BC; Schröder S; Ofner D; Böcker W; Fischer-Colbrie R; Schmid KW
Histopathology; 1995 Apr; 26(4):357-61. PubMed ID: 7607625
[TBL] [Abstract][Full Text] [Related]
16. Distribution of chromogranin A and secretogranin I (chromogranin B) in neuroendocrine cells and tumors.
Lloyd RV; Cano M; Rosa P; Hille A; Huttner WB
Am J Pathol; 1988 Feb; 130(2):296-304. PubMed ID: 3341449
[TBL] [Abstract][Full Text] [Related]
17. Chromogranin-A expression in neoplastic neuroendocrine cells and prognosis in colorectal cancer.
Secco GB; Campora E; Fardelli R; Lapertosa G; De Lucchi F; Gianquinto D; Bonfante P
Tumori; 1996; 82(4):390-3. PubMed ID: 8890977
[TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine differentiation in colorectal carcinomas.
Syversen U; Halvorsen T; Mårvik R; Waldum HL
Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):667-74. PubMed ID: 8590163
[TBL] [Abstract][Full Text] [Related]
19. Levels and molecular forms of chromogranins in human childhood neuroblastomas and ganglioneuromas.
Eder U; Fischer-Colbrie R; Kogner P; Leitner B; Bjellerup P; Winkler H
Neurosci Lett; 1998 Aug; 253(1):17-20. PubMed ID: 9754794
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical localization of chromogranins A and B and secretogranin II in normal, hyperplastic and neoplastic prostate.
Schmid KW; Helpap B; Tötsch M; Kirchmair R; Dockhorn-Dworniczak B; Böcker W; Fischer-Colbrie R
Histopathology; 1994 Mar; 24(3):233-9. PubMed ID: 7515371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
